Echo Therapeutics, Inc. Selected for Wearable Technology Feature on Worldwide Business with kathy ireland®
ISELIN, N.J., May 26, 2015 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced that it was selected to be included in a wearable fitness tracking and monitoring technology segment on Worldwide Business with kathy ireland®, a weekly business program.
The segment, which will appear on Fox Business Network (as pd. prog) in the United States and Bloomberg International (as pd. prog.) globally, will be hosted by Ireland and will illustrate the features and benefits of Echo's continuous glucose monitoring technology in the wearable health market.
"We are very excited to forge this new collaboration with kathy ireland Worldwide®. This production allows us to share our message on a global platform and the opportunity to broaden and expand our reach," said Scott Hollander, Echo's President and CEO. "We look forward to communicating and demonstrating the potential of our continuous glucose monitoring system in the wearable health market because tracking glucose is important to everyone, not just to people with diabetes."
"We are excited that Echo will be featured in the Wearables segment of the show," commented JL Haber, Vice President of Programming for Worldwide Business with kathy ireland®. "We always look for innovative technology and Echo's non-invasive CGM is a perfect fit. The wearable technology space is exploding with step counting devices and the addition of glucose monitoring will provide individuals with tremendous insight for this critical parameter."
About Echo Therapeutics
Echo Therapeutics is developing its non-invasive, wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company's CGM to be used in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the outpatient diabetes and hospital settings. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
About Worldwide Business with kathy ireland®
Worldwide Business with kathy ireland® is a weekly business television program featuring real-world insights from corporate executives from all over the globe.
Worldwide Business with kathy ireland® airs Sunday evenings throughout North America on Fox Business Network (as pd. prog) and to over 50 countries throughout the world through Bloomberg International.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's CGM System, the failure of future development and preliminary marketing efforts related to Echo's CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell Echo's CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2014, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(732) 549-0128
MMP Press Contact:
Gila Stern
Communications Director
MMP (USA), Inc.
[email protected]
561-988-9616 ext. 269
Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx
SOURCE Echo Therapeutics, Inc.
Share this article